NO341584B1 - Metastin derivater og anvendelse derav - Google Patents

Metastin derivater og anvendelse derav

Info

Publication number
NO341584B1
NO341584B1 NO20091487A NO20091487A NO341584B1 NO 341584 B1 NO341584 B1 NO 341584B1 NO 20091487 A NO20091487 A NO 20091487A NO 20091487 A NO20091487 A NO 20091487A NO 341584 B1 NO341584 B1 NO 341584B1
Authority
NO
Norway
Prior art keywords
suppressive activity
activity
hormone secretion
metastine
derivatives
Prior art date
Application number
NO20091487A
Other languages
English (en)
Norwegian (no)
Other versions
NO20091487L (no
Inventor
Taiji Asami
Naoki Nishizawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20091487L publication Critical patent/NO20091487L/no
Publication of NO341584B1 publication Critical patent/NO341584B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NO20091487A 2006-10-25 2009-04-16 Metastin derivater og anvendelse derav NO341584B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006290536 2006-10-25
JP2007021387 2007-01-31
JP2007221911 2007-08-28
PCT/JP2007/071169 WO2008050897A1 (en) 2006-10-25 2007-10-24 Metastin derivatives and use thereof

Publications (2)

Publication Number Publication Date
NO20091487L NO20091487L (no) 2009-07-07
NO341584B1 true NO341584B1 (no) 2017-12-11

Family

ID=38925530

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091487A NO341584B1 (no) 2006-10-25 2009-04-16 Metastin derivater og anvendelse derav

Country Status (33)

Country Link
US (2) US7786083B2 (cg-RX-API-DMAC10.html)
EP (1) EP2081955B1 (cg-RX-API-DMAC10.html)
JP (2) JP2010507565A (cg-RX-API-DMAC10.html)
KR (1) KR101424306B1 (cg-RX-API-DMAC10.html)
AR (1) AR063367A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007309969B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0717441B8 (cg-RX-API-DMAC10.html)
CA (1) CA2667537C (cg-RX-API-DMAC10.html)
CL (1) CL2007003053A1 (cg-RX-API-DMAC10.html)
CR (1) CR10799A (cg-RX-API-DMAC10.html)
CY (1) CY1116627T1 (cg-RX-API-DMAC10.html)
DK (1) DK2081955T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP099279A (cg-RX-API-DMAC10.html)
ES (1) ES2539430T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20125568B (cg-RX-API-DMAC10.html)
HR (1) HRP20150819T1 (cg-RX-API-DMAC10.html)
HU (1) HUE025291T2 (cg-RX-API-DMAC10.html)
IL (1) IL198046A (cg-RX-API-DMAC10.html)
JO (1) JO3048B1 (cg-RX-API-DMAC10.html)
MA (1) MA30887B1 (cg-RX-API-DMAC10.html)
ME (1) ME00786B (cg-RX-API-DMAC10.html)
MX (1) MX2009004148A (cg-RX-API-DMAC10.html)
MY (1) MY145975A (cg-RX-API-DMAC10.html)
NO (1) NO341584B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ576375A (cg-RX-API-DMAC10.html)
PE (1) PE20081469A1 (cg-RX-API-DMAC10.html)
PL (1) PL2081955T3 (cg-RX-API-DMAC10.html)
PT (1) PT2081955E (cg-RX-API-DMAC10.html)
RS (1) RS54083B1 (cg-RX-API-DMAC10.html)
SI (1) SI2081955T1 (cg-RX-API-DMAC10.html)
TN (1) TN2009000140A1 (cg-RX-API-DMAC10.html)
TW (1) TWI404726B (cg-RX-API-DMAC10.html)
WO (1) WO2008050897A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063221A1 (ja) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
WO2006001499A2 (en) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP5279021B2 (ja) * 2006-04-26 2013-09-04 国立大学法人京都大学 Gpr54アゴニスト活性を有する新規化合物
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
US8110639B2 (en) * 2006-11-17 2012-02-07 Solvay Advanced Polymers, L.L.C. Transparent and flame retardant polysulfone compositions
US20110118172A1 (en) * 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
EP2275433B1 (en) * 2008-04-30 2017-06-07 Kyoto University Metastin derivative and use thereof
WO2010013762A1 (ja) 2008-07-30 2010-02-04 武田薬品工業株式会社 メタスチン誘導体およびその用途
US8716228B2 (en) 2009-05-27 2014-05-06 Yeda Research And Development Co. Ltd. GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
EP2585091B1 (en) * 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Sustained-release formulation comprising a metastin derivative
EP2755690B1 (en) 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
CA2915055C (en) * 2013-06-12 2021-07-20 Merck Patent Gmbh Hydroxyethylene derivatives for the treatment of arthrosis
WO2015112703A1 (en) * 2014-01-22 2015-07-30 The Johns Hopkins University Compositions and methods for treating diabetes
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
CN107428803A (zh) * 2015-02-08 2017-12-01 耶路撒冷希伯来大学伊萨姆研究发展有限公司 用于治疗恶性增殖性疾病的肽
CN116813705A (zh) * 2017-07-05 2023-09-29 凯惠科技发展(上海)有限公司 一种肽类化合物、其应用及含其的组合物
TWI795462B (zh) * 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
JP2023521388A (ja) * 2020-04-08 2023-05-24 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー 脂肪肝疾患に対する修飾キスペプチン受容体作用薬
WO2025217074A1 (en) * 2024-04-08 2025-10-16 Radionetics Oncology, Inc. Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060264A2 (en) * 2003-01-06 2004-07-22 Takeda Pharmaceutical Company Limited Metastin derivatives and their use
EP1577323A1 (en) * 2002-12-26 2005-09-21 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
WO2006001499A2 (en) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74827A (en) 1984-05-21 1989-06-30 Salk Inst For Biological Studi Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es) 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2229201A1 (en) 1995-10-19 1997-04-24 Satoshi Sasaki Quinoline derivatives, their production and use
JPH09169735A (ja) 1995-10-19 1997-06-30 Takeda Chem Ind Ltd キノリン誘導体、その製造法および用途
AU2382097A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規g蛋白質共役型レセプター蛋白質、そのdnaおよびそのリガンド
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
MXPA01013367A (es) 1999-06-28 2002-07-02 Basf Ag Metodo para la prevencion del crecimiento tumoral.
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
AU1889101A (en) 1999-12-17 2001-06-25 Takeda Chemical Industries Ltd. Process for producing kiss-1 peptide
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001075104A1 (fr) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Nouvelle proteine, adn codant pour celle-ci, et son procede de production
US7834141B1 (en) 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru) 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja) 2000-11-29 2003-01-29 Takeda Chem Ind Ltd 医薬組成物およびその製造法
JP2002320496A (ja) 2001-02-26 2002-11-05 Takeda Chem Ind Ltd 新規マウス型KiSS−1レセプタータンパク質およびそのDNA
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
WO2002092829A1 (en) 2001-05-17 2002-11-21 Takeda Chemical Industries, Ltd. Process for producing peptide
DE60219645T2 (de) * 2001-09-19 2007-08-09 Takeda Pharmaceutical Co. Ltd. Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
AU2003201854A1 (en) * 2002-01-11 2003-07-30 Takeda Chemical Industries, Ltd. PROCESS FOR PRODUCING KiSS-1 PEPTIDE
JP2003300906A (ja) 2002-04-12 2003-10-21 Daiichi Fine Chemical Co Ltd がん転移抑制因子の安定化
AU2003272964A1 (en) * 2002-10-09 2004-05-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
MXPA05004380A (es) 2002-10-25 2005-11-23 Paradigm Therapeutics Ltd Mamiferos gpr54 knock out y metodos de investigacion que los utilizan.
JP4804714B2 (ja) 2002-12-26 2011-11-02 武田薬品工業株式会社 メタスチン誘導体およびその用途
KR100595364B1 (ko) 2003-02-20 2006-07-03 재단법인 목암생명공학연구소 Lk8 단백질을 유효성분으로 포함하는 항암제
US7754220B2 (en) * 2003-03-12 2010-07-13 Takeda Pharmaceutical Company Limited Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
EP1464652A1 (en) 2003-04-02 2004-10-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
US20050026224A1 (en) 2003-04-28 2005-02-03 Follettie Maximillian T. Methods and compositions for modulating G-protein coupled receptor 54
WO2004101747A2 (en) 2003-05-07 2004-11-25 The General Hospital Corporation Identification and use of gpr54 and its ligands for reproductive disorders and contraception
WO2004106289A1 (en) 2003-05-30 2004-12-09 Prozymex A/S Protease inhibitors
CA2544473C (en) 2003-11-03 2013-08-13 Beijing Sunbio Biotech Co., Ltd. A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
WO2005095973A2 (en) 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005117939A2 (en) 2004-04-23 2005-12-15 Applied Research Systems Ars Holding N.V. Use of gpcr54 ligands for the treatment of infertility
WO2007084211A2 (en) 2005-11-11 2007-07-26 The General Hospital Corporation Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20070244048A1 (en) 2006-03-20 2007-10-18 Marsh Donald J Neuromedin U receptor agonists and uses thereof
US20100215637A1 (en) * 2006-03-28 2010-08-26 Biopharmica Ltd Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
CA2701612A1 (en) 2007-10-05 2009-04-09 Takeda Pharmaceutical Company Limited Neuromedin u derivative
US20110118172A1 (en) 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
EP2340047A1 (en) 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1577323A1 (en) * 2002-12-26 2005-09-21 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
WO2004060264A2 (en) * 2003-01-06 2004-07-22 Takeda Pharmaceutical Company Limited Metastin derivatives and their use
WO2006001499A2 (en) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof

Also Published As

Publication number Publication date
CA2667537A1 (en) 2008-05-02
US20110059888A1 (en) 2011-03-10
TWI404726B (zh) 2013-08-11
AR063367A1 (es) 2009-01-21
PE20081469A1 (es) 2008-12-25
JO3048B1 (ar) 2016-09-05
US8765909B2 (en) 2014-07-01
CA2667537C (en) 2017-01-17
MY145975A (en) 2012-05-31
CY1116627T1 (el) 2017-03-15
HUE025291T2 (en) 2016-02-29
EP2081955A1 (en) 2009-07-29
GEP20125568B (en) 2012-07-10
DK2081955T3 (da) 2015-06-15
ME00786B (me) 2011-12-20
MX2009004148A (es) 2009-05-01
PL2081955T3 (pl) 2015-10-30
BRPI0717441B1 (pt) 2019-07-02
ECSP099279A (es) 2009-06-30
JP5686825B2 (ja) 2015-03-18
HK1130500A1 (en) 2009-12-31
AU2007309969B2 (en) 2012-04-19
NZ576375A (en) 2011-07-29
IL198046A0 (en) 2011-08-01
JP2010507565A (ja) 2010-03-11
MA30887B1 (fr) 2009-11-02
TN2009000140A1 (en) 2010-10-18
HRP20150819T1 (hr) 2015-09-11
TW200823232A (en) 2008-06-01
KR20090090315A (ko) 2009-08-25
CR10799A (es) 2009-06-09
KR101424306B1 (ko) 2014-08-01
PT2081955E (pt) 2015-07-10
SI2081955T1 (sl) 2015-06-30
RS54083B1 (sr) 2015-10-30
US20090215700A1 (en) 2009-08-27
WO2008050897A1 (en) 2008-05-02
IL198046A (en) 2014-06-30
US7786083B2 (en) 2010-08-31
ES2539430T3 (es) 2015-06-30
AU2007309969A1 (en) 2008-05-02
NO20091487L (no) 2009-07-07
EP2081955B1 (en) 2015-05-06
BRPI0717441B8 (pt) 2021-05-25
AU2007309969A2 (en) 2009-06-04
BRPI0717441A2 (pt) 2013-11-19
JP2013075913A (ja) 2013-04-25
CL2007003053A1 (es) 2008-08-08

Similar Documents

Publication Publication Date Title
NO20091487L (no) Metastin derivater og anvendelse derav
NO20082595L (no) Metastinderivater og deres anvendelse derav
TW200607816A (en) Metastin derivatives and use thereof
UY29357A1 (es) Agonistas de pyy y sus usos
CL2020002026A1 (es) Inhibidor de fap.
ATE525033T1 (de) Optische sonde zur abgabe von licht
CY1122010T1 (el) Εξενδινη για θεραπευτικη αγωγη διαβητη και μειωση σωματικου βαρους
EA200901026A1 (ru) Электродная решетка
DOP2013000212A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
DK1751302T3 (da) Analytsensorer og fremgangsmåder til fremstilling og anvendelse heraf
EA201100908A1 (ru) Расширенные растворимые полипептиды рн20 и их использование
MX2009002471A (es) Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.
EP2285989A4 (en) NEW TARGET MOLECULES FOR REGULATING ANGIONESE
EA201101525A1 (ru) Фармацевтическая композиция
UY29258A1 (es) Ácidos hidroxibifenilcarboxílicos y derivados, procedimientos para prepararlos y su uso
MX2010010505A (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
UY28443A1 (es) Derivados sustituidos del dióxido de tiazol-benzoisotiazol, procedimiento para su preparación y su uso.
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
CR9722A (es) Derivados de benzilpiperazina y su uso medico
UY29020A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.-
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
WO2008070552A3 (en) Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
AR108283A2 (es) Derivados de metastina
WO2007059455A3 (en) Non-biofouling, universal redox electrode and measurement system